BioMarin says Inozyme deal to strengthen enzyme therapies portfolio

After BioMarin Pharmaceutical (BMRN) announced a definitive agreement to acquire and Inozyme Pharma (INZY) for $4.00 per share in an all-cash transaction for a total consideration of approximately $270M, the company stated: “The acquisition will strengthen BioMarin’s enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701, which is currently being assessed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. The condition is associated with increased cardiovascular mortality risk across all age groups, especially in infants. It is also associated with severe rickets and osteomalacia in children and adults. Data from the first Phase 3 pivotal study of INZ-701 in children is expected in early 2026, with potential regulatory approval in 2027.”